Qaly-time; new medical technology, cost-effectiveness and guidelines.
Nieuwe medische technologie: afweging tussen kosten en gezondheidswinst
The cost-effectiveness criterion – the incremental cost per Quality adjusted life year – could play a valuable role in these decisions. Currently, this potential is only partially exploited. oreover, it is unclear what is an acceptable price per QALY – how much is society willing to pay for a QALY?
Policymakers could provide more guidance in this respect. Including cost-effectiveness as one of the criteria in formulating clinical practice guidelines seems a promising policy option.
This publication is in Dutch.